Literature DB >> 17209524

Inhibitors of hypoxia-inducible factor-1 signaling.

Vladimir E Belozerov1, Erwin G Van Meir.   

Abstract

Hypoxia is a universal feature of solid tumors that arises as the tumor mass outgrows stromal vascular supply. Hypoxia-inducible factor (HIF)-1, a transcription factor upregulated in hypoxia, orchestrates a range of adaptive responses that allow tumor cells to survive oxygen deprivation. Important information regarding the role of HIF-1 in tumor biology was gained from tumor biopsy studies in which HIF-1 expression was strongly associated with poor patient prognosis, and from animal studies in which genetic ablation of HIF-1 signaling retarded tumor growth. These findings motivated an intensive search for small-molecule inhibitors of the HIF-1 pathway. This review describes the progress toward the identification of specific inhibitors of HIF-1, and discuss the first examples of HIF-1-targeted therapeutics to enter clinical development.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17209524

Source DB:  PubMed          Journal:  Curr Opin Investig Drugs        ISSN: 1472-4472


  14 in total

1.  Sulfonamides as a new scaffold for hypoxia inducible factor pathway inhibitors.

Authors:  Chalet Tan; Rita G de Noronha; Narra S Devi; Adnan A Jabbar; Stefan Kaluz; Yuan Liu; Suazette Reid Mooring; K C Nicolaou; Binghe Wang; Erwin G Van Meir
Journal:  Bioorg Med Chem Lett       Date:  2011-06-28       Impact factor: 2.823

Review 2.  Exciting new advances in neuro-oncology: the avenue to a cure for malignant glioma.

Authors:  Erwin G Van Meir; Costas G Hadjipanayis; Andrew D Norden; Hui-Kuo Shu; Patrick Y Wen; Jeffrey J Olson
Journal:  CA Cancer J Clin       Date:  2010 May-Jun       Impact factor: 508.702

3.  Structure-activity relationship of 2,2-dimethyl-2H-chromene based arylsulfonamide analogs of 3,4-dimethoxy-N-[(2,2-dimethyl-2H-chromen-6-yl)methyl]-N-phenylbenzenesulfonamide, a novel small molecule hypoxia inducible factor-1 (HIF-1) pathway inhibitor and anti-cancer agent.

Authors:  Jiyoung Mun; Adnan Abdul Jabbar; Narra Sarojini Devi; Yuan Liu; Erwin G Van Meir; Mark M Goodman
Journal:  Bioorg Med Chem       Date:  2012-05-14       Impact factor: 3.641

Review 4.  Hypoxia, stem cells and bone tumor.

Authors:  Wen Zeng; Rong Wan; Yuehuan Zheng; Shree Ram Singh; Yiyong Wei
Journal:  Cancer Lett       Date:  2011-09-29       Impact factor: 8.679

5.  Binding Model for the Interaction of Anticancer Arylsulfonamides with the p300 Transcription Cofactor.

Authors:  Qi Shi; Shaoman Yin; Stefan Kaluz; Nanting Ni; Narra Sarojini Devi; Jiyoung Mun; Danzhu Wang; Krishna Damera; Weixuan Chen; Sarah Burroughs; Suazette Reid Mooring; Mark M Goodman; Erwin G Van Meir; Binghe Wang; James P Snyder
Journal:  ACS Med Chem Lett       Date:  2012-06-21       Impact factor: 4.345

6.  Selective inhibition of hypoxia-inducible factor 1α ameliorates adipose tissue dysfunction.

Authors:  Kai Sun; Nils Halberg; Mahmood Khan; Ulysses J Magalang; Philipp E Scherer
Journal:  Mol Cell Biol       Date:  2012-12-17       Impact factor: 4.272

7.  Identification of a novel small molecule HIF-1alpha translation inhibitor.

Authors:  Takuhito Narita; Shaoman Yin; Christine F Gelin; Carlos S Moreno; Manuel Yepes; K C Nicolaou; Erwin G Van Meir
Journal:  Clin Cancer Res       Date:  2009-09-29       Impact factor: 12.531

8.  Design and in vitro activities of N-alkyl-N-[(8-R-2,2-dimethyl-2H-chromen-6-yl)methyl]heteroarylsulfonamides, novel, small-molecule hypoxia inducible factor-1 pathway inhibitors and anticancer agents.

Authors:  Jiyoung Mun; Adnan Abdul Jabbar; Narra Sarojini Devi; Shaoman Yin; Yingzhe Wang; Chalet Tan; Deborah Culver; James P Snyder; Erwin G Van Meir; Mark M Goodman
Journal:  J Med Chem       Date:  2012-07-24       Impact factor: 7.446

9.  Arylsulfonamide KCN1 inhibits in vivo glioma growth and interferes with HIF signaling by disrupting HIF-1α interaction with cofactors p300/CBP.

Authors:  Shaoman Yin; Stefan Kaluz; Narra S Devi; Adnan A Jabbar; Rita G de Noronha; Jiyoung Mun; Zhaobin Zhang; Purushotham R Boreddy; Wei Wang; Zhibo Wang; Thomas Abbruscato; Zhengjia Chen; Jeffrey J Olson; Ruiwen Zhang; Mark M Goodman; K C Nicolaou; Erwin G Van Meir
Journal:  Clin Cancer Res       Date:  2012-08-24       Impact factor: 12.531

Review 10.  Hypoxia inducible factor pathway inhibitors as anticancer therapeutics.

Authors:  Erwin G Van Meir; Binghe Wang; Sarah K Burroughs; Stefan Kaluz; Danzhu Wang; Ke Wang
Journal:  Future Med Chem       Date:  2013-04       Impact factor: 3.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.